Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment

Multiple Sclerosis Journal

Volumn 20, Issue 14, 2014, Pages 1872-1880

  Jensen, H B ^a,b   Ravnborg, M ^c   Mamoei, S ^b   Dalgas, U ^d   Stenager, E ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Sonderborg Hospital   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

axonal loss; demyelination; Multiple sclerosis; rehabilitation

Indexed keywords

4 AMINOPYRIDINE; FAMPRIDINE; DELAYED RELEASE FORMULATION; POTASSIUM CHANNEL BLOCKING AGENT;

5 TIMES SIT TO STAND TEST; 9 HOLE PEG TEST; ADULT; ARM MOVEMENT; ARTICLE; BODY MOVEMENT; COGNITION; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; FUNCTION TEST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; SIX SPOT STEP TEST; SLOW RELEASE FORMULATION; SYMBOL DIGIT MODALITIES TEST; THERAPY EFFECT; TIMED 25 FOOT WALK; TREATMENT RESPONSE; AGE; CONTROLLED STUDY; INTERMETHOD COMPARISON; MIDDLE AGED; PHYSICAL CAPACITY; SEX; WALK TEST; ARM; COHORT ANALYSIS; DELAYED RELEASE FORMULATION; EXERCISE TEST; LEG; MOTOR PERFORMANCE; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

4-AMINOPYRIDINE; ADULT; ARM; COGNITION; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; EXERCISE TEST; FEMALE; HUMANS; LEG; MALE; MIDDLE AGED; MOTOR SKILLS; MULTIPLE SCLEROSIS; POTASSIUM CHANNEL BLOCKERS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84910652368     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514533844     Document Type: Article

References (39)

1. Solari A, Uitdehaag B, Giuliani G, et al. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev. 2003 ;: CD001330
2. Judge SI, Bever CT. Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 ; 111: 224-259
3. Compston A, Coles A. Multiple sclerosis. Lancet. 2008 ; 372: 1502-1517
4. Gottberg K, Einarsson U, Ytterberg C, et al. Health-related quality of life in a population-based sample of people with multiple sclerosis in Stockholm County. Mult Scler. 2006 ; 12: 605-612
5. Hobart J, Lamping D, Fitzpatrick R, et al. The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure. Brain. 2001 ; 124: 962-973
6. Heesen C, Bohm J, Reich C, et al. Patient perception of bodily functions in multiple sclerosis: Gait and visual function are the most valuable. Mult Scler. 2008 ; 14: 988-991
7. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: A randomised, double-blind, controlled trial. Lancet. 2009 ; 373: 732-738
8. Bostock H, Sears TA, Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol. 1981 ; 313: 301-315
9. Hayes KC. The use of 4-aminopyridine (fampridine) in demyelinating disorders. CNS Drug Rev. 2004 ; 10: 295-316
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452
11. Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010 ; 68: 494-502
12. Kieseier BC, Pozzilli C. Assessing walking disability in multiple sclerosis. Mult Scler. 2012 ; 18: 914-924
13. Thoumie P, Lamotte D, Cantalloube S, et al. Motor determinants of gait in 100 ambulatory patients with multiple sclerosis. Mult Scler. 2005 ; 11: 485-491
14. Broekmans T, Gijbels D, Eijnde BO, et al. The relationship between upper leg muscle strength and walking capacity in persons with multiple sclerosis. Mult Scler. 2013 ; 19: 112-119
15. Dalgas U, Severinsen K, Overgaard K. Relations between 6 minute walking distance and 10 meter walking speed in patients with multiple sclerosis and stroke. Arch Phys Med Rehabil. 2012 ; 93: 1167-1172
16. Nieuwenhuis MM, Van Tongeren H, Sorensen PS, et al. The Six Spot Step Test: A new measurement for walking ability in multiple sclerosis. Mult Scler. 2006 ; 12: 495-500
17. Moller AB, Bibby BM, Skjerbaek AG, et al. Validity and variability of the 5-Repetition Sit-To-Stand test in patients with multiple sclerosis. Disabil Rehabil. 2012 ; 34: 2251-2258
18. Rudick RA, Cutter G, Baier M, et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology. 2001 ; 56: 1324-1330
19. Rudick RA, Cutter G, Reingold S. The Multiple Sclerosis Functional Composite: A new clinical outcome measure for multiple sderosis trials. Mult Scler. 2002 ; 8: 359-365
20. Lord SR, Murray SM, Chapman K, Munro B, Tiedemann A. Sit-to-stand performance depends on sensation, speed, balance, and psychological status in addition to strength in older people. J Gerontol A Biol Sci Med Sci. 2002 ; 57: M539 - M543
21. McCarthy EK, Horvat MA, Holtsberg PA, et al. Repeated chair stands as a measure of lower limb strength in sexagenarian women. J Gerontol A Biol Sci Med Sci. 2004 ; 59: 1207-1212
22. Mong Y, Teo TW, Ng SS. 5-Repetition Sit-To-Stand test in subjects with chronic stroke: Reliability and validity. Arch Phys Med Rehabil. 2010 ; 91: 407-413
23. Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: Improving assessment sensitivity with Box-And-Block and Nine-Hole Peg tests. ; 1988 ; 1988. 850.
24. Parmenter BA, Weinstock-Guttman B, Garg N, et al. Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test. Mult Scler. 2007 ; 13: 52-57
25. Bronnum-Hansen H, Koch-Henriksen N, Stenager E. The Danish Multiple Sclerosis Registry. Scand J Public Health. 2011 ; 39: 62-64
26. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 ; 69: 292-302
27. Kragt JJ, van der Linden FA, Nielsen JM, et al. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler. 2006 ; 12: 594-598
28. Hobart J, Blight AR, Goodman A, Lynn F, et al. Timed 25-foot walk: Direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology. 2013 ; 80: 1509-1517
29. Liang MH, Fossel AH, Larson MG. Comparisons of five health status instruments for orthopedic evaluation. Med Care. 1990 ; 28: 632-642
30. Coleman CI, Sobieraj DM, Marinucci LN. Minimally important clinical difference of the Timed 25-Foot Walk Test: Results from a randomized controlled trial in patients with multiple sclerosis. Curr Med Res Opin. 2012 ; 28: 49-56
31. Stefoski D, Davis FA, Fitzsimmons WE, et al. 4-Aminopyridine in multiple sclerosis: Prolonged administration. Neurology. 1991 ; 41: 1344-1348
32. Whitney SL, Wrisley DM, Marchetti GF, et al. Clinical measurement of sit-to-stand performance in people with balance disorders: Validity of data for the Five-Times-Sit-to-Stand Test. Physical therapy. 2005 ; 85: 1034-1045
33. Oxford Grice K, Vogel KA, Le V, et al. Adult norms for a commercially available Nine Hole Peg Test for finger dexterity. Am J Occup Ther. 2003 ; 57: 570-573
34. Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: A randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler. 2007 ; 13: 357-368
35. Blum D, Meador K, Biton V, et al. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology. 2006 ; 67: 400-406
36. Smits RC, Emmen HH, Bertelsmann FW, et al. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: A pilot study. Neurology. 1994 ; 44: 1701-1705
37. Polman CH, Bertelsmann FW, van Loenen AC, et al. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol. 1994 ; 51: 292-296
38. Ravnborg M, Sorensen PS, Christiansen P, et al. Central motor conduction as a measure of disease progression in early multiple sclerosis. Eur J Neurol. 1995 ; 1: 233-241
39. Jensen HB, Ravnborg M, Dalgas U, et al. 4-Aminopyridine for symptomatic treatment of multiple sclerosis: A systematic review. Ther Adv Neurol Disord. 2014 ; 7: 97-113